AIM
GTHX

Aigen Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Aigen Investment Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-90,985
Closed -$1.05M – 1148
2020
Q3 		$1.05M Buy
+90,985
New +$1.5M 0.13% 242

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aigen Investment Management's GTHX Position: Q4 2020 in Review

Aigen Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2020, closing a stake of 90,985 shares — an estimated $1.05M sold.

Aigen Investment Management first reported a position in GTHX in Q3 2020 and held it in 1 quarter. The position peaked at $1.05M in Q3 2020. 125 funds tracked by Wall St. Rank hold GTHX as of Q4 2020.

  • Aigen Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 90,985 G1 Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1.05M.
  • Aigen Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Aigen Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $1.05M in Q3 2020.
  • 125 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.